Serum Neurofilament Light is Increased in Multiple System Atrophy of Cerebellar Type and in Repeat-expansion Spinocerebellar Ataxias: a Pilot Study

Overview

Journal J Neurol

Specialty Neurology

Date 2018 May 9

PMID 29737427

Citations 30

Authors

Carlo Wilke

Friedemann Bender

Stefanie N Hayer

Kathrin Brockmann

Ludger Schols

Jens Kuhle

Matthis Synofzik

Affiliations

Soon will be listed here.

Abstract

Blood biomarkers in degenerative ataxias are still largely missing. Here, we aimed to provide piloting proof-of-concept that serum Neurofilament light (NfL) could offer a promising peripheral blood biomarker in degenerative ataxias. Specifically, as a marker of neuronal damage, NfL might (1) help to differentiate multiple system atrophy of cerebellar type (MSA-C) from sporadic adult-onset ataxia (SAOA), and (2) show increases in repeat-expansion spinocerebellar ataxias (SCAs) which might be amenable to treatment in the future. To explore these two hypotheses, we measured serum NfL levels by single-molecule array (Simoa) technique in 115 subjects, comprising patients with MSA-C (n = 25), SAOA (n = 25), the most frequent repeat-expansion SCAs (SCA 1, 2, 3 and 6) (n = 20), and age-matched controls (n = 45). Compared to controls, NfL was significantly increased in MSA-C, with levels significantly higher than in SAOA (AUC = 0.74 (0.59-0.89), mean and 95% confidence interval, p = .004). NfL was also significantly increased in SCA patients as compared to controls (AUC = 0.91 (0.81-1.00), p < .001), including NfL increases in SCA1 and SCA3. These findings provide first proof-of-concept that NfL might provide a promising peripheral biomarker in degenerative ataxias, e.g. supporting the differentiation of MSA-C from SAOA, and indicating neuronal damage in repeat-expansion SCAs.

Citing Articles

Specific Biomarkers in Spinocerebellar Ataxia Type 3: A Systematic Review of Their Potential Uses in Disease Staging and Treatment Assessment.

Soto-Pina A, Pulido-Alvarado C, Dulski J, Wszolek Z, Magana J Int J Mol Sci. 2024; 25(15).

PMID: 39125644 PMC: 11311810. DOI: 10.3390/ijms25158074.

Circulating levels of neurofilament light chain as a biomarker of infarct and white matter hyperintensity volumes after ischemic stroke.

Holmegaard L, Jensen C, Pedersen A, Blomstrand C, Blennow K, Zetterberg H Sci Rep. 2024; 14(1):16180.

PMID: 39003344 PMC: 11246414. DOI: 10.1038/s41598-024-67232-1.

Blood levels of neurofilament light are associated with disease progression in a mouse model of spinocerebellar ataxia type 3.

Mengel D, Wellik I, Schuster K, Jarrah S, Wacker M, Ashraf N Dis Model Mech. 2023; 16(9).

PMID: 37664882 PMC: 10499033. DOI: 10.1242/dmm.050144.

Multidimensional biomarkers for multiple system atrophy: an update and future directions.

Wan L, Zhu S, Chen Z, Qiu R, Tang B, Jiang H Transl Neurodegener. 2023; 12(1):38.

PMID: 37501056 PMC: 10375766. DOI: 10.1186/s40035-023-00370-0.

Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy.

Guo Y, Shen X, Huang S, Chen S, Wang H, Zhang W NPJ Parkinsons Dis. 2023; 9(1):40.

PMID: 36922526 PMC: 10017699. DOI: 10.1038/s41531-023-00481-5.

References

Sako W, Murakami N, Izumi Y, Kaji R . Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis. J Neurol Sci. 2015; 352(1-2):84-7. DOI: 10.1016/j.jns.2015.03.041. View

Gilman S, Wenning G, Low P, Brooks D, Mathias C, Trojanowski J . Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9):670-6. PMC: 2676993. DOI: 10.1212/01.wnl.0000324625.00404.15. View

Scoles D, Meera P, Schneider M, Paul S, Dansithong W, Figueroa K . Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature. 2017; 544(7650):362-366. PMC: 6625650. DOI: 10.1038/nature22044. View

Toonen L, Rigo F, van Attikum H, van Roon-Mom W . Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat in Spinocerebellar Ataxia Type 3 Mice. Mol Ther Nucleic Acids. 2017; 8:232-242. PMC: 5504086. DOI: 10.1016/j.omtn.2017.06.019. View

Giordano I, Harmuth F, Jacobi H, Paap B, Vielhaber S, Machts J . Clinical and genetic characteristics of sporadic adult-onset degenerative ataxia. Neurology. 2017; 89(10):1043-1049. DOI: 10.1212/WNL.0000000000004311. View

Skillback T, Farahmand B, Bartlett J, Rosen C, Mattsson N, Nagga K . CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival. Neurology. 2014; 83(21):1945-53. DOI: 10.1212/WNL.0000000000001015. View

Disanto G, Barro C, Benkert P, Naegelin Y, Schadelin S, Giardiello A . Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol. 2017; 81(6):857-870. PMC: 5519945. DOI: 10.1002/ana.24954. View

Jacobi H, Bauer P, Giunti P, Labrum R, Sweeney M, Charles P . The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology. 2011; 77(11):1035-41. PMC: 3174068. DOI: 10.1212/WNL.0b013e31822e7ca0. View

Bacioglu M, Maia L, Preische O, Schelle J, Apel A, Kaeser S . Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron. 2016; 91(1):56-66. DOI: 10.1016/j.neuron.2016.05.018. View

10.

Wilke C, Preische O, Deuschle C, Roeben B, Apel A, Barro C . Neurofilament light chain in FTD is elevated not only in cerebrospinal fluid, but also in serum. J Neurol Neurosurg Psychiatry. 2016; 87(11):1270-1272. DOI: 10.1136/jnnp-2015-312972. View

11.

Abdo W, van de Warrenburg B, Munneke M, van Geel W, Bloem B, Kremer H . CSF analysis differentiates multiple-system atrophy from idiopathic late-onset cerebellar ataxia. Neurology. 2006; 67(3):474-9. DOI: 10.1212/01.wnl.0000227891.25592.8c. View

12.

Menke R, Gray E, Lu C, Kuhle J, Talbot K, Malaspina A . CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol. 2015; 2(7):748-55. PMC: 4531057. DOI: 10.1002/acn3.212. View

13.

Hansson O, Janelidze S, Hall S, Magdalinou N, Lees A, Andreasson U . Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. Neurology. 2017; 88(10):930-937. PMC: 5333515. DOI: 10.1212/WNL.0000000000003680. View

14.

Gattringer T, Pinter D, Enzinger C, Seifert-Held T, Kneihsl M, Fandler S . Serum neurofilament light is sensitive to active cerebral small vessel disease. Neurology. 2017; 89(20):2108-2114. PMC: 5711505. DOI: 10.1212/WNL.0000000000004645. View

15.

Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius A . Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med. 2016; 54(10):1655-61. DOI: 10.1515/cclm-2015-1195. View

16.

Schmitz-Hubsch T, Tezenas Du Montcel S, Baliko L, Berciano J, Boesch S, Depondt C . Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006; 66(11):1717-20. DOI: 10.1212/01.wnl.0000219042.60538.92. View

17.

Faul F, Erdfelder E, Buchner A, Lang A . Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41(4):1149-60. DOI: 10.3758/BRM.41.4.1149. View

18.

Matsushima M, Yabe I, Oba K, Sakushima K, Mito Y, Takei A . Comparison of Different Symptom Assessment Scales for Multiple System Atrophy. Cerebellum. 2015; 15(2):190-200. DOI: 10.1007/s12311-015-0686-4. View

19.

Zetterberg H . Neurofilament Light: A Dynamic Cross-Disease Fluid Biomarker for Neurodegeneration. Neuron. 2016; 91(1):1-3. DOI: 10.1016/j.neuron.2016.06.030. View

20.

Paulson H, Shakkottai V, Clark H, Orr H . Polyglutamine spinocerebellar ataxias - from genes to potential treatments. Nat Rev Neurosci. 2017; 18(10):613-626. PMC: 6420820. DOI: 10.1038/nrn.2017.92. View